ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Phase II Randomized Study of Physiologic Testosterone Replacement in Premenopausal, HIV-Positive Women

This study is currently recruiting participants.
Verified by FDA Office of Orphan Products Development, May 1998

Sponsors and Collaborators: FDA Office of Orphan Products Development
Charles Drew University of Medicine and Science
Information provided by: FDA Office of Orphan Products Development
ClinicalTrials.gov Identifier: NCT00004400
  Purpose

OBJECTIVES: I. Determine whether physiologic testosterone replacement can increase fat-free mass, therefore contributing to weight maintenance, improved muscle function, and quality of life in HIV-infected women.

II. Examine the mechanism of testosterone-induced increase in fat-free mass.


Condition Intervention Phase
HIV Infections
Cachexia
Drug: testosterone
Phase II

MedlinePlus related topics:   AIDS   

Drug Information available for:   Testosterone    Methyltestosterone    Oxymesterone    Testosterone enanthate    Testosterone Propionate    Testosterone undecanoate   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double-Blind, Placebo Control, Efficacy Study

Further study details as provided by FDA Office of Orphan Products Development:

Estimated Enrollment:   56
Study Start Date:   April 1997

Detailed Description:

PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled study. Patients are randomized to one of three arms.

Arm I: Patients receive two placebo transdermal patches applied twice a week (every 3-4 days).

Arm II: Patients receive one testosterone transdermal patch and one placebo transdermal patch applied twice a week (every 3-4 days).

Arm III: Patients receive two testosterone transdermal patches applied twice a week (every 3-4 days).

Patients receive 12 weeks of treatment in the absence of adverse reaction or health deterioration. Patients are followed on day 1, every 2 weeks during treatment, and at the end of the recovery period. Quality of life is assessed before treatment begins and at weeks 6 and 12.

  Eligibility
Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

  • Histologically confirmed premenopausal HIV-positive women who have experienced 5-15% weight loss

--Prior/Concurrent Therapy--

  • Endocrine therapy: At least 3 months since megestrol At least 3 months since anabolic or androgenic steroids At least 3 months since oral contraceptives At least 3 months since Depo-Provera No concurrent hormone replacement therapy
  • Other: Concurrent retroviral or protease inhibitors allowed, dosage must be stable At least 3 months since ketoconazole At least 6 weeks since the initiation of protease inhibitors

--Patient Characteristics--

  • Hepatic: No significant liver disease SGOT/SGPT no greater than 3 times upper limit of normal (ULN) Alkaline phosphatase no greater than 3 times ULN Bilirubin no greater than 2 mg/dL No medical complications due to alcohol abuse
  • Renal: Not specified
  • Cardiovascular: No significant cardiovascular disease No uncontrolled hypertension
  • Other: Testosterone level (early morning) less than 30 ng/dL Normal gastrointestinal function as indicated by: Absence of diarrhea Normal D-xylose absorption test No acute opportunistic infections or infectious illness No malignant disease No history of breast cancer No history of endometrial cancer No fever of known or unknown origin No unremitting diarrhea defined as: At least 4 watery stools per day OR More than 4 watery stools recently OR Acute change in stool habit with fever No significant respiratory disease No diabetes No illicit drugs within the past 6 months No history of hyperandrogenic disorders such as: Hirsutism Polycystic ovary disease Not pregnant or lactating
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00004400

Locations
United States, California
Charles R. Drew University of Medicine and Science     Recruiting
      Los Angeles, California, United States, 90059
      Contact: Shalender Bhasin     213-563-9353        
Los Angeles County Harbor-UCLA Medical Center     Recruiting
      Torrance, California, United States, 90509
      Contact: G. Beall     310-222-2444        
United States, Missouri
Washington University School of Medicine     Recruiting
      Saint Louis, Missouri, United States, 63110
      Contact: K. Yarashaski     314-362-9700        

Sponsors and Collaborators
FDA Office of Orphan Products Development
Charles Drew University of Medicine and Science

Investigators
Study Chair:     Shalender Bhasin     Charles Drew University of Medicine and Science    
  More Information


Study ID Numbers:   199/13251, CDUMS-FDR001397
First Received:   October 18, 1999
Last Updated:   June 23, 2005
ClinicalTrials.gov Identifier:   NCT00004400
Health Authority:   United States: Federal Government

Keywords provided by FDA Office of Orphan Products Development:
cachexia  
disease-related problem/condition  
human immunodeficiency virus infection  
immunologic disorders and infectious disorders  
nutrition
quality of life
rare disease
viral infection

Study placed in the following topic categories:
Sexually Transmitted Diseases, Viral
Acquired Immunodeficiency Syndrome
Rare Diseases
Quality of Life
Cachexia
Methyltestosterone
Emaciation
Immunologic Deficiency Syndromes
Testosterone 17 beta-cypionate
Virus Diseases
Body Weight
Signs and Symptoms
Testosterone
HIV Seropositivity
HIV Infections
Sexually Transmitted Diseases
Weight Loss
Body Weight Changes
Retroviridae Infections

Additional relevant MeSH terms:
RNA Virus Infections
Slow Virus Diseases
Immune System Diseases
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Infection
Hormones
Pharmacologic Actions
Anabolic Agents
Therapeutic Uses
Lentivirus Infections
Androgens

ClinicalTrials.gov processed this record on November 20, 2008




Links to all studies - primarily for crawlers